Johnson & Johnson (JNJ) Raw Materials (2012 - 2018)
Johnson & Johnson's (JNJ) quarterly Raw Materials came in at $1.1 billion in Q4 2018, down 2.28% year-on-year from $1.1 billion in Q4 2017, and down 7.32% quarter-over-quarter from $1.2 billion in Q3 2018.
Johnson & Johnson (JNJ) Raw Materials (2012 - 2018) Analysis & Trends
Johnson & Johnson has disclosed Raw Materials across 6 years of filings, most recently posting $1.1 billion for Q4 2018.
- Raw Materials for Q4 2018 came in at $1.1 billion, down 2.28% year-over-year; the trailing twelve-month figure through Dec 2018 was $1.1 billion (down 2.28% YoY), and the FY2018 annual result was $1.1 billion, down 2.28% from the prior year.
- Raw Materials came in at $1.1 billion for Q4 2018 at Johnson & Johnson, down from $1.2 billion in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.2 billion in Q4 2014 to a low of $936.0 million in Q1 2016.
- The 4-year median for Raw Materials is $1.1 billion (2017), against an average of $1.1 billion.
- Across the five-year window, Raw Materials fell 22.9% in 2016 and gained 19.75% in 2017, its largest moves.
- Johnson & Johnson's Raw Materials stood at $1.2 billion in 2014, then fell by 22.9% to $936.0 million in 2016, then climbed by 21.79% to $1.1 billion in 2017, then retreated by 2.28% to $1.1 billion in 2018.
- The last three Raw Materials figures came in at $1.1 billion (Q4 2018), $1.2 billion (Q3 2018), and $1.2 billion (Q3 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 30, 2018 | 1.11 Bn |
| Sep 30, 2018 | 1.20 Bn |
| Jul 1, 2018 | 1.17 Bn |
| Dec 31, 2017 | 1.14 Bn |
| Jan 1, 2017 | 952.00 Mn |
| Jan 3, 2016 | 936.00 Mn |
| Dec 28, 2014 | 1.21 Bn |
| Dec 29, 2013 | 1.22 Bn |
| Dec 30, 2012 | 1.42 Bn |
| Jan 1, 2012 | 1.21 Bn |